Clinical Trial Update: Expanded Access Single Named Patient Program With Elotuzumab (BMS-901608) for the Treatment of Patient R-A With Relapsed/Refractory Multiple Myeloma

View source ↗

Summary

Expanded-access single-patient program for the monoclonal antibody elotuzumab in a relapsed/refractory multiple myeloma patient (R-A); the program is no longer …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Empliciti (elotuzumab)

Snippet

Sponsor: Sundar Jagannath | Conditions: Multiple Myeloma | Status: NO_LONGER_AVAILABLE